Fig 1: Different expression patterns of CEACAM7 and CEA in gastric non-neoplastic lesions and gastric carcinomas. Consecutive sections were used for analysis. No immunoreaction for CEACAM7 was detected in normal mucosa (A). CEACAM7 was localized on the apical surface of chronic atrophic gastritis (C), low grade GIN (E) and high grade GIN (G). CEA was localized on the apical luminal surface of normal mucosa (B), chronic atrophic gastritis (D), low-grade GIN(F), and high-grade GIN (H). Both CEACAM7 (I) and CEA (J) was localized on the whole surface of gastric cancerous cells. (DAB as chromogen, counterstained with Harris hematoxylin, 200X).
Fig 2: Co-localization of CEACAM7 and CEA in the tissue of gastric carcinoma (Laser confocal microscopy analysis in a representative section). Positive expression for CEACAM7 (A, red) or CEA (B, green) in the membrane and cytoplasm of cancerous cells (red). C, Merged image without nuclear staining; co-expression of CEACAM7 and CEA is observed (yellow). D, Merged image with nucleus stained by DAPI (blue). (200X).
Fig 3: Co-expression of CEACAM7 and CEA in gastric carcinomas. A&B, Negative staining for CEACAM7 (A) and CEA (D) in a well differentiated gastric carcinoma. C&D, CEACAM7 (C) and CEA (D) staining was negative in the well differentiated area (cancer cells are ranged in gland-like form) and positive in the poorly differentiated area (brown color) of a gastric carcinoma. E&F, Positive staining for CEACAM7 (E) and CEA (F) in a poorly differentiated gastric carcinoma. A&B, C&D, and E&F are adjacent serial sections, respectively.(DAB as chromogen, counterstained with Harris hematoxylin, 50X).
Fig 4: Kaplan-Meier curves for postoperative survival. The median survival time of patients with CEACAM7 and CEA double-positivity was shorter than that of patients with double-negativity (log-rank test: P = 0.001). But, there was no significant difference between the median survival time of patients with single-positivity and double-negativity (P = 0.391).
Supplier Page from Abcam for Anti-CEACAM7 antibody [BAC2]